Karyopharm Therapeutics Inc.KPTINASDAQ
LOADING
|||
Revenue Growth Under Pressure
Trending lower, below historical average.
Left:
||||
Year-over-year revenue growth rate
Latest
16.12%
↓ 90% below average
Average (39q)
164.96%
Historical baseline
Range
High:6024.52%
Low:-100.00%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 16.12% |
| Q2 2025 | 26.37% |
| Q1 2025 | -1.73% |
| Q4 2024 | -21.25% |
| Q3 2024 | -9.36% |
| Q2 2024 | 29.16% |
| Q1 2024 | -1.84% |
| Q4 2023 | -6.28% |
| Q3 2023 | -4.18% |
| Q2 2023 | -2.89% |
| Q1 2023 | 15.24% |
| Q4 2022 | -7.10% |
| Q3 2022 | -8.91% |
| Q2 2022 | -16.76% |
| Q1 2022 | -62.25% |
| Q4 2021 | 235.03% |
| Q3 2021 | 66.76% |
| Q2 2021 | -2.83% |
| Q1 2021 | -33.73% |
| Q4 2020 | 64.53% |
| Q3 2020 | -36.35% |
| Q2 2020 | 84.77% |
| Q1 2020 | 0.23% |
| Q4 2019 | 37.62% |
| Q3 2019 | 38.51% |
| Q2 2019 | 6024.52% |
| Q1 2019 | -24.76% |
| Q4 2018 | -13.81% |
| Q3 2018 | -98.80% |
| Q2 2018 | 98.91% |
| Q1 2018 | 551.89% |
| Q4 2017 | 0.00% |
| Q3 2017 | -100.00% |
| Q2 2017 | -95.59% |
| Q1 2017 | 44.68% |
| Q4 2016 | -2.08% |
| Q3 2016 | -18.64% |
| Q2 2016 | 0.00% |
| Q1 2016 | -100.00% |
| Q4 2015 | -66.67% |